Key result
Oxprenolol 40 mg b.d. for preventing cardiac events after uncomplicated myocardial infarction yielded no conclusive results as the trial was terminated early due to better than expected prognosis.
Why the study?
Does oxprenolol prevent cardiac events in patients following uncomplicated acute myocardial infarction?
RCT (n=313)
Double-blind
Randomized
Does oxprenolol prevent cardiac events in patients following uncomplicated acute myocardial infarction?
The trial of oxprenolol for secondary prevention after uncomplicated MI was terminated early due to lower-than-expected event rates, highlighting challenges in powering such studies.
Answers are grounded in this paper and cite their sources.
Trial inconclusive for oxprenolol post uncomplicated MI; leaves open beta-blocker efficacy in low-risk cohorts.
A randomised double–blind placebo controlled trial was designed to evaluate the efficacy of oxprenolol 40 mg b.d. in the prevention of cardiac events between 2–56 days following uncomplicated acute myocardial infarction. Three hundred and thirteen male and female patients were recruited over three years; the study was terminated when it became evident that a conclusive result could not be obtained within any reasonable extension of the planned trial duration. This was largely due to the better than expected prognosis of selected patients. Our study highlights some of the difficulties in clinical trials in this field
No takes yet. Share an insight, caveat, or question.
Taylor S.H. (1981) conducted an RCT in Uncomplicated acute myocardial infarction (n=313). Oxprenolol vs. Placebo was evaluated on Cardiac events. Oxprenolol 40 mg b.d. for preventing cardiac events after uncomplicated myocardial infarction yielded no conclusive results as the trial was terminated early due to better than expected prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: